1. The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate.
- Author
-
Wang SS, Chou NK, Chi NH, Huang SC, Wu IH, Wang CH, Yu HY, Chen YS, Tsao CI, Ko WJ, and Shun CT
- Subjects
- Actuarial Analysis, Adult, Aged, Cyclosporine adverse effects, Drug Therapy, Combination, Everolimus, Female, Follow-Up Studies, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Mycophenolic Acid adverse effects, Mycophenolic Acid therapeutic use, Retrospective Studies, Sirolimus adverse effects, Sirolimus therapeutic use, Survival Rate, Time Factors, Cyclosporine therapeutic use, Heart Transplantation immunology, Heart Transplantation mortality, Mycophenolic Acid analogs & derivatives, Sirolimus analogs & derivatives
- Abstract
Introduction: Heart transplantation has become the best available therapy for patients with refractory end-stage heart failure. Cyclosporine (CsA) and mycophenolate mofetil (MMF) are the 2 FDA-approved drugs to prevent posttransplant acute rejection episodes. The purpose of this study was to evaluate the result of heart transplantation treated with CsA and everolimus (EVL), compared with that of patients treated with CsA and MMF., Materials and Methods: From 2000 to 2009 heart transplantation was performed in 239 patients among whom we enrolled 93 patients with a serum creatinine values
- Published
- 2010
- Full Text
- View/download PDF